Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.

ABSTRACT:

Importance

The Age-Related Eye Disease Study (AREDS) formulation for the treatment of age-related macular degeneration (AMD) contains vitamin C, vitamin E, beta carotene, and zinc with copper. The Age-Related Eye Disease Study 2 (AREDS2) assessed the value of substituting lutein/zeaxanthin in the AREDS formulation because of the demonstrated risk for lung cancer from beta carotene in smokers and former smokers and because lutein and zeaxanthin are important components in the retina.

Objective

To further examine the effect of lutein/zeaxanthin supplementation on progression to late AMD.

Design, setting, participants

The Age-Related Eye Disease Study 2 is a multicenter, double-masked randomized trial of 4203 participants, aged 50 to 85 years, at risk for developing late

SUBMITTER: Age-Related Eye Disease Study 2 (AREDS2) Research Group 

PROVIDER: S-EPMC4636082 | biostudies-literature | 2014 Feb

REPOSITORIES: biostudies-literature